XENEライブシグナル | Getagraph.comで利益を最大化

売る 109476 min ago

@ $49.08

発行日: 14 2月 2024 @ 01:05

リターン: -13.83%

前回のシグナル: 2月 13 - 05:25

前回のシグナル: 買う

リターン: -0.13 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:41):

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada...

Stats
本日の出来高	226 761
平均出来高	359 750
時価総額	3.19B
EPS	$0 ( 2024-02-29 )
次の収益日	( $-0.690 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-15.49
ATR14	$0.0640 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-11	Von Seggern Christopher	Buy	100 000	Stock Option (Right to Buy)
2024-03-11	Aulin Sherry	Buy	100 000	Stock Option (Right to Buy)
2024-03-11	Kenney Christopher John	Buy	100 000	Stock Option (Right to Buy)
2024-03-11	Empfield James R.	Buy	65 000	Stock Option (Right to Buy)
2024-03-11	Robin Sherrington	Buy	65 000	Stock Option (Right to Buy)

INSIDER POWER
59.32
Last 100 transactions
Buy: 2 181 840 \| Sell: 619 411

ボリューム相関

長: 0.10 (neutral)

短: 0.81 (strong)

Signal:(54.277) Same movement expected

Xenon Pharmaceuticals Inc 相関

10 最も正の相関
PAIC	0.905
SVAC	0.827
GOODM	0.825
TLGT	0.818

10 最も負の相関
RAVN	-0.9
NETE	-0.871
BOCH	-0.849
MMAC	-0.824
SHSP	-0.824
AMRB	-0.807

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Xenon Pharmaceuticals Inc 相関 - 通貨/商品

0.30
( neutral )

-0.13
( neutral )

0.00
( neutral )

-0.18
( neutral )

0.65
( moderate )

-0.63
( weak negative )

Xenon Pharmaceuticals Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-3.54M (0.00 %)
EPS:	$-2.73

FY	2023
収益:	$0
総利益:	$-3.54M (0.00 %)
EPS:	$-2.73

FY	2022
収益:	$9.43M
総利益:	$-96.33M (-1 021.13 %)
EPS:	$-2.07

FY	2021
収益:	$18.44M
総利益:	$0.00 (0.00 %)
EPS:	$-1.770

Financial Reports:

No articles found.

Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.